The greenshoe option, explained through Holtec's 7.5M shares
Underwriters can sell up to 15% more IPO shares than a company issues. Holtec Nuclear's filing this week hits that cap exactly — here's why it exists.
Every IPO prospectus contains an "over-allotment option" clause, and almost every retail reader skips past it — it reads like boilerplate, buried between the underwriting discount and the lock-up section. It isn't boilerplate. It's the main tool banks have to keep a brand-new stock from cratering in its first weeks, and understanding it explains why some IPOs trade oddly calm right around the offer price while others gap wildly on day one.
The problem the option exists to solve
When a company goes public, the underwriters commit to selling a fixed number of shares at a fixed price before anyone knows how the stock will actually trade. If demand disappoints and the stock drops below the offer price on debut, early buyers who paid full price are sitting on an instant loss — a bad look that follows the underwriter into the next deal and can spook buyers out of the stock for weeks. Underwriters need a way to step in and buy shares to support the price without simply eating the loss themselves. That's what the over-allotment option — commonly called the "greenshoe," after Green Shoe Manufacturing, the first company whose 1960s IPO used it — is built to do.
How it actually works
The mechanism is a short sale dressed up as an option. Underwriters agree to sell investors more shares than the company is actually issuing — typically up to 15% more — even though those extra shares don't exist yet. They're selling short. Then, for a window of roughly 30 days after pricing, one of two things happens depending on which direction the stock moves:
- If the stock trades up, the underwriters exercise the greenshoe: they buy the extra shares from the company at the original offer price and use them to cover the short. The company gets extra capital, the underwriters lock in a clean trade, and no one had to touch the open market.
- If the stock trades down, the underwriters instead buy those shares back in the open market at the now-lower price, covering the short at a profit while their buying provides real demand that cushions the decline. The greenshoe becomes a built-in, SEC-sanctioned price-support mechanism — one of the only forms of active stabilization regulators allow, precisely because the underwriter is using its own short position rather than manipulating the market with someone else's money.
Either way, the company is protected from a scenario where the stock free-falls with no buyer of last resort, and the underwriter's incentive to prop up the price for those 30 days is baked directly into the trade rather than left to goodwill.
A live example: Holtec Nuclear's filing this week
Holtec Nuclear Corporation launched the roadshow for its IPO on September 8, 2026, offering 50,000,000 shares of Class A common stock at a proposed price of $15 to $18 — roughly $825 million at the midpoint, ahead of a targeted valuation of up to $10.2 billion when it lists on the Nasdaq Global Select Market and Nasdaq Texas under ticker HNUC. J.P. Morgan, Guggenheim Securities, Goldman Sachs, Citigroup and BofA Securities are leading the syndicate, with pricing expected around September 17.
Alongside the base offering, Holtec is granting the underwriters a 30-day option to buy up to an additional 7,500,000 shares. Run the math: 7.5 million is exactly 15% of the 50 million base shares — the standard ceiling on greenshoe size, not a number chosen at random. Zorro's IPO pipeline has been tracking Holtec's filing since it went public, and this is the kind of mechanical detail that's easy to miss in a headline about a $10.2 billion valuation but that shapes how the stock actually trades once it opens.
What to actually watch for
A few things worth checking whenever an S-1 crosses your screen:
| Signal | What it suggests |
|---|---|
| Greenshoe set at or near the full 15% | Underwriters expect meaningful demand and want maximum flexibility to stabilize either direction |
| Greenshoe set well below 15%, or omitted | Less common; can signal a smaller or more cautious deal structure |
| Option exercised in full shortly after pricing | Stock traded up — a reasonably strong signal of demand exceeding the base allocation |
| Heavy buying in the days after listing with the stock hovering near the offer price | Classic sign of active stabilization — the underwriter using the short to defend the price |
None of this is disclosed in real time; the exercise of the option typically only surfaces later, in the company's next quarterly filing or a press mention. But knowing the mechanism changes how you read the first 30 days of trading. A stock that seems suspiciously glued to its offer price isn't necessarily "boring" — it may be exactly where the underwriter wants it. That dynamic sits right alongside what happens once the greenshoe window closes and the real lock-up period begins; how lock-up expirations work covers the next phase of the same supply story, once insiders — not underwriters — become the ones who can sell.
The greenshoe only ever affects the first month of trading, and it only ever works in the company's and underwriters' favor by design — it's not a signal retail investors can trade against, just a piece of plumbing worth recognizing when a newly listed stock is behaving in a way that looks stabilized rather than organic. It's one more reason first-week price action in the recently priced cohort tells you as much about underwriting mechanics as it does about genuine investor demand.